Study #2021-1069
A Phase 1a/1b open-label study to assess the safety, pharmacokinetics, and antitumor activity of oral TACH101 in patients with advanced or metastatic solid tumors.
MD Anderson Study Status
Enrolling
Treatment Agent
TACH101
Description
The main objective for part 1a of the study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) and to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of oral TACH101 in participants with advanced and metastatic solid tumors. For part 1b, the main objective is the objective response rate (ORR) as assessed by radiographic progression measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Cancer, Metastatic Solid Tumor, Solid Tumor
Study phase:
Phase I
Physician name:
Apostolia Tsimberidou
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-491-2084
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.